CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We are very excited to launch our new website! Please take a few moments to click around and explore...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...